| abstract |
This refers to compounds of the formula (1) wherein: R 1 is hydrogen, lower alkyl, lower alkoxy, hydroxyl, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl amino or halogen; R2 is phenyl, optionally substituted by lower alkyl, lower alkoxy, halogen, trifluoromethyl, amino, lower alkyl amino or di-lower alkyl amino, 2,3-dihydro-benzofuran-5-yl, chroman-6-yl, naphthalen -2-yl, indan-5-yl, lower alkylene-phenyl, 5,6,7,8-tetrahydro-naphthalenyl, 2,3-dihydro-isoindole-3-yl, 1,2,3,4-tetrahydro- naphthalenyl, benzofuran-2-yl, benzo [b] thiophene-2-yl, lower alkyl-phenyl, 3,4-dihydro-1H-isoquinolin-2-yl or thiophene-3-yl; R3 and R4 are, independently of each other, hydrogen or lower alkyl; R5 is hydrogen, lower alkyl, -CH2OH or -CH2NR6R7; R6 and R5 are, independently of each other, hydrogen, lower alkyl, - (CH2) n-phenyl, cycloalkyl, - (CH2) m-morpholinyl or together with the N atom form a C4-6 saturated ring; n is 0-3; m is 2-3; X is -NR8- or -O-; or X and R5 are, together,> N (CH2) 2-; or X and R3 are, together,> N (CH2) 3-; and R8 is hydrogen or lower alkyl; and its pharmaceutically acceptable acid addition salts, with the exception of the following compounds (6-chloro-2-phenyl-4-quinolinyl) - (+) - 2-aminobutanol; (6-methyl-2-phenyl-4-quinolinyl) - (+) - 2-aminobutanol; (6-Methoxo-2-phenyl-4-quinolinyl) - (+) - 2-aminobutanol; and (8-methoxy-2-phenyl-4-quinolinyl) - (+) - 2-aminobutanol, which can be used for the treatment of diseases related to specific NMDA receptor blockers. |